News - BioSpace
WEBCalifornia Tops Biopharma Job Openings So Far in 2024, Per Data. For the first eight months of 2024, California had the most job postings live on BioSpace —37.7% more than Massachusetts. Last year, Massachusetts ranked No.1 for the same time period. BioSpace is the digital hub for life science news and jobs.
BioSpace: Biotech, Pharmaceutical and Clinical Research News
WEB2024 Q2 Job Market Report: More People Competing for Fewer Job Openings. For the second quarter of 2024, there were 25% fewer jobs posted live on BioSpace compared to the same quarter of 2023. The year-over-year job response rate rose from 14.6% to 15.3%. July 11, 2024. ·.
HEK 293 Cells: Background, Advantages and Applications
WEBJun 18, 2021 · Human Embryonic Kidney 293 (HEK 293) cells are one of the most frequently used cell lines for biotechnology and research studies. These cells are popular because they are fast-growing and robust. Additionally, due to the efficiency of HEK 293 cells, they generate exogenous proteins used in biomedical and pharmaceutical research.
Xbiome Acquires Clinical-Stage Program Targeting Ulcerative Colitis
WEBApr 25, 2022 · Xbiome currently has three clinical-stage programs in its pipeline focused on Ulcerative Colitis, Diabetic Foot Ulcer and Graft vs. Host Disease. In addition, Xbiome has earlier-stage programs in autism spectrum and immuno-oncology. Xbiome was founded in 2017 and has established its culturomics and AI platforms since its inception.
AstraZeneca’s Imfinzi Scores Lung Cancer Wins With FDA’s
WEBAug 16, 2024 · AstraZeneca touted two lung cancer victories on Thursday with its blockbuster PD-1 inhibitor Imfinzi (durvalumab) securing the FDA’s nod for a perioperative label expansion in non-small cell lung cancer, as well as the regulator’s Priority Review and Breakthrough Therapy designations for small cell lung cancer.. The perioperative approval came as a bit of a surprise.
AstraZeneca’s Imfinzi-Lynparza Combo Wins Landmark EU Nod for ...
WEBAug 14, 2024 · The European Commission on Wednesday signed off on AstraZeneca ’s combination regimen of Imfinzi (durvalumab) and Lynparza (olaparib) for the treatment of certain endometrial cancer patients with advanced or recurrent disease.. The regulatory victory marks the “first-ever approval for a combination of an immunotherapy and PARP inhibitor in endometrial cancer,” Dave Fredrickson, executive ...
Career Advice for Life Sciences Professionals - BioSpace
WEBAug 1, 2024 · Carina Clingman is the founder of The Collaboratory Career Hub, an online community for people interested in working in biotech. She’s also the founder and CEO of Recruitomics Consulting, which specializes in talent acquisition and talent strategy for startup biotechs. Career Advice. Career Coach: Transition Into a Career in Biotech.
Wet Lab vs Dry Lab: Challenges, Benefits and Skills Required
WEBJan 25, 2023 · In a wet lab, testing and analyses are performed using physical samples, chemicals and liquids. Biological samples, drugs and fluids are all tested in a wet lab. In other words, “wet” materials are tested. In a dry lab, testing and analyses is performed using data, coding and computer systems. Modeling and analysis normally take place in a ...
House Lawmakers Raise Alarm About US Biopharma Companies
WEBAug 21, 2024 · With the BIOSECURE Act poised for a vote in the House of Representatives, a congressional committee is urging the FDA to look into U.S. biopharmaceutical companies that have allegedly worked with the Chinese military to conduct clinical trials in Xinjiang.. In a letter to FDA Commissioner Robert Califf, the House Select Committee on the CCP flagged the “alarming practice” of some U.S ...
Grail Lays Off About 350 Employees, Puts Brakes on New Hires
WEBAug 14, 2024 · Less than two months after Illumina spun off Grail, the company is laying off about 350 employees, it announced on Tuesday. The reduction represents about 25% of its workforce as of June 30, according to a Securities and Exchange Commission filing. Illumina completed the spinoff on June 24. Grail, which focuses on …
Skip to content